Alexion Pharmaceuticals Inc. (ALXN) Now Covered by Analysts at Brean Capital
Brean Capital assumed coverage on shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) in a research note published on Tuesday. The brokerage issued a buy rating and a $221.00 price objective on the biopharmaceutical company’s stock.
ALXN has been the subject of several other reports. Cowen and Company restated a buy rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 8th. Credit Suisse Group AG upgraded shares of Alexion Pharmaceuticals from a neutral rating to an outperform rating in a report on Saturday, July 9th. Royal Bank Of Canada started coverage on shares of Alexion Pharmaceuticals in a report on Tuesday, July 12th. They set an outperform rating and a $188.00 target price for the company. Vetr upgraded shares of Alexion Pharmaceuticals from a buy rating to a strong-buy rating and set a $171.50 target price for the company in a report on Wednesday, June 8th. Finally, Leerink Swann lifted their target price on shares of Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an outperform rating in a report on Monday, September 26th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Alexion Pharmaceuticals has an average rating of Buy and an average price target of $178.32.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 2.30% during trading on Tuesday, reaching $126.25. The company’s stock had a trading volume of 230,265 shares. The firm’s 50-day moving average price is $128.48 and its 200-day moving average price is $135.06. The company has a market capitalization of $28.31 billion, a price-to-earnings ratio of 317.21 and a beta of 1.33. Alexion Pharmaceuticals has a one year low of $110.56 and a one year high of $193.45.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.17 by $0.04. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The company earned $753 million during the quarter, compared to analysts’ expectations of $743.18 million. During the same quarter last year, the business earned $1.44 earnings per share. The business’s quarterly revenue was up 18.4% on a year-over-year basis. On average, equities analysts anticipate that Alexion Pharmaceuticals will post $4.67 earnings per share for the current year.
In related news, CEO David Hallal sold 332 shares of the company’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $45,530.48. Following the completion of the transaction, the chief executive officer now owns 189,266 shares of the company’s stock, valued at approximately $25,955,939.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Carsten Thiel sold 1,000 shares of the company’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $125.94, for a total transaction of $125,940.00. Following the completion of the transaction, the executive vice president now directly owns 40,579 shares of the company’s stock, valued at approximately $5,110,519.26. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of ALXN. Evercore Wealth Management LLC increased its position in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 83 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund purchased a new position in shares of Alexion Pharmaceuticals during the second quarter valued at $1,056,000. Kentucky Retirement Systems purchased a new position in shares of Alexion Pharmaceuticals during the second quarter valued at $2,224,000. Mason Street Advisors LLC purchased a new position in shares of Alexion Pharmaceuticals during the second quarter valued at $3,523,000. Finally, Cowen Group Inc. increased its position in shares of Alexion Pharmaceuticals by 36.4% in the second quarter. Cowen Group Inc. now owns 4,500 shares of the biopharmaceutical company’s stock valued at $525,000 after buying an additional 1,200 shares in the last quarter. 96.34% of the stock is owned by institutional investors.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.